No additional benefit from atropine to stop axial lengthening

Article

No effect when used with orthokeratology lenses for 2 years.

No additional benefit from atropine to stop axial lengthening

Dr Zhi Chen and coauthors from the Department of Ophthalmology and Visual Science, Fudan University Eye Ear Nose and Throat Hospital, Shanghai, China, reported that adding atropine therapy for 2 years in patients who wore orthokeratology lenses did not result in a more positive effect on stopping axial length elongation compared with the use of orthokeratology lenses alone.

The investigators reached this conclusion after a retrospective analysis1 of the axial length status of 73 eyes of 73 patients who wore orthokeratology lenses for 3 years.

During the first year in which the patients wore the lenses, the axial elongation was 0.30 mm or more in all patients.

At this time, the patients were divided into 2 groups; 37 were treated with the lenses and atropine at a dose of 0.01% instilled nightly and 36 continued with the lenses alone. The patients continued with these treatments for 2 years.

The researchers compared the axial elongation over time in both groups.

Comparison of the groups

The authors found that in the group treated with lenses and atropine, the respective mean axial elongation values were0.47 ± 0.15, 0.21 ± 0.15, and 0.23 ± 0.13 mm during years 1, 2, and 3; the respective values in the lens-alone group were 0.41 ± 0.09, 0.30 ± 0.11 and 0.20 ± 0.13 mm.

The cumulative axial elongation over 3 years for both groups were virtually the same and that the overall change in the axial length did not differ significantly (P = 0.262) between the groups.

The researchers also found that the baseline myopic refractive error had a significant (P < 0.001) impact on axial elongation over the 3 years. The baseline parameters, age, lens design and treatment did not significantly impact the axial length elongation.

The authors concluded that atropine 0.01% instillation in patients with rapid progression of myopia and poor responders to orthokeratology lens use did not significantly change the 3-year axial elongation outcome when compared with use of orthokeratology lenses alone.

Reference
1. Chen Z, Zhou J, Xue F, Qu X, Zhou X. Two-year add-on effect of using low concentration atropine in poor responders of orthokeratology in myopic children. Br J Ophthalmol. Published online July 21, 2022; http://dx.doi.org/10.1136/bjophthalmol-2020-317980
Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.